jounce.png
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
January 13, 2021 08:00 ET | Jounce Therapeutics, Inc.
- INNATE is a robust Phase 1 study designed to dose escalate quickly and demonstrate proof of concept for JTX-8064 monotherapy and PD-1i combinations - - Tumor-specific expansion cohorts to...
jounce.png
Jounce Therapeutics Announces Update on Vopratelimab Program
November 02, 2020 07:00 ET | Jounce Therapeutics, Inc.
- No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis- - First patient dosed in SELECT trial of vopratelimab in combination with JTX-4014 in...
jounce.png
Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Friday, November 6, 2020
October 30, 2020 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
September 01, 2020 08:30 ET | Jounce Therapeutics, Inc.
  – Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead to Make $85 Million Upfront Payment and $35 Million Equity Investment – FOSTER CITY, Calif. and...
jounce.png
Jounce Therapeutics to Participate in a Fireside Chat at BTIG Virtual Biotechnology Conference 2020
August 04, 2020 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference
June 10, 2020 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 09, 2020 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019
October 31, 2019 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Present at Upcoming Investor Conferences in September
August 28, 2019 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
August 07, 2019 06:30 ET | Jounce Therapeutics, Inc.
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...